Revance Appoints Biotech and Pharmaceutical Executive, Olivia C. Ware, and Fintech and Payments Thought Leader and Entrepreneur, Carey O’Connor Kolaja, to its Board of Directors - Seite 2
Ms. Ware is President of Davidson College Board of Visitors and member of the Davidson Board of Trustees. She graduated from Davidson College and received her MBA from the University of North Carolina at Chapel Hill.
Ms. Kolaja has been a thought leader and executive in the financial services and payment industry for 25 years, helping businesses develop product strategy, optimize operations and drive growth. She is currently the CEO of AU10TIX, the global leader in automated identity intelligence and cyber fraud prevention. Prior, Ms. Kolaja was the Global Chief Product Officer at Citi Fintech and Vice President of Global Consumer Products at PayPal. In these roles she led international teams to design, deploy, and operate global fintech and payments products. Ms. Kolaja is an author and has been featured on FOX Business, CNBC, and industry publications. She was named one of The Top 10 Women in Fintech by Fintech Magazine in 2020 and was recognized by Innotribe as one of the leading Women in Fintech bridging the gender gap.
Ms. Kolaja is currently the Chairman of Everest Effect, a crisis recovery platform, and a board member for Waves for Water, an international non-profit that aims to expand the availability of clean water around the world. She is a graduate of the University of Indiana Business School, with a BS in Business, and a graduate of the executive program of Stanford University.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance owns a unique portfolio of premium products and services for U.S. aesthetics practices, including the exclusive U.S. distribution rights to the RHA Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.